Press-release Combination treatment with Vargatef® and docetaxel contributes to statistically significant tumor reduction in patients with progressive adenocarcinoma of the lung in comparison with docetaxel in monotherapy
Терапия препаратом Варгатеф® (нинтеданиб*) в комбинации с доцетакселом способствует значительному уменьшению и замедлению роста опухоли у пациентов с аденокарциномой легкого после 1-й линии химиотерапии по сравнению с монотерапией доцетакселом. У пациентов с прогрессирующей аденокарциномой, получавш...
Main Author: | - - |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2015-09-01
|
Series: | Современная онкология |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26997 |
Similar Items
-
Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
by: Kristensen Vessela, et al.
Published: (2007-10-01) -
Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
by: Kosuke Hamai, et al.
Published: (2023-04-01) -
Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
by: Wenchao Yang, et al.
Published: (2022-08-01) -
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
by: Andreas Venizelos, et al.
Published: (2022-08-01) -
Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
by: Hugo Ford, et al.
Published: (2015-07-01)